Jefferies Financial Group Issues Positive Forecast for Zoetis (NYSE:ZTS) Stock Price

Zoetis (NYSE:ZTS) had its target price raised by analysts at Jefferies Financial Group from $83.00 to $85.00 in a note issued to investors on Friday. Jefferies Financial Group‘s price target would indicate a potential upside of 7.88% from the company’s previous close.

A number of other research analysts also recently issued reports on ZTS. The Goldman Sachs Group started coverage on Zoetis in a research note on Friday, October 16th. They issued a “neutral” rating and a $74.00 price objective for the company. TD Cowen decreased their target price on Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 25th. Weiss Ratings upgraded Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, October 29th. William Blair downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and a consensus price target of $101.25.

Zoetis Stock Performance

Shares of NYSE ZTS traded down $3.32 during midday trading on Friday, reaching $78.79. The company’s stock had a trading volume of 1,993,844 shares, compared to its average volume of 5,444,132. Zoetis has a 12-month low of $68.77 and a 12-month high of $132.49. The firm has a 50 day moving average price of $75.59 and a 200-day moving average price of $92.82. The stock has a market capitalization of $32.56 billion, a P/E ratio of 12.98, a PEG ratio of 1.32 and a beta of 0.67. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, November 5th. The company reported $1.75 EPS for the quarter, beating analysts’ consensus estimates of $1.51 by $0.24. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. Zoetis’s revenue was down 1.3% on a year-over-year basis. During the same period last year, the business posted $1.70 earnings per share. As a group, equities analysts predict that Zoetis will post 6.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ZTS. University of Texas Texas AM Investment Management Co. bought a new position in Zoetis during the second quarter worth about $25,000. Dunhill Financial LLC raised its position in shares of Zoetis by 519.3% in the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock valued at $25,000 after purchasing an additional 296 shares during the period. Cassaday & Co Wealth Management LLC bought a new stake in shares of Zoetis in the first quarter valued at approximately $28,000. First Command Advisory Services Inc. lifted its stake in shares of Zoetis by 3,881.8% during the 3rd quarter. First Command Advisory Services Inc. now owns 438 shares of the company’s stock valued at $31,000 after buying an additional 427 shares in the last quarter. Finally, Wellington Grp LLC lifted its stake in shares of Zoetis by 6,675.0% during the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after buying an additional 267 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Adjusted earnings were $1.75 per share, above the $1.51 consensus, and revenue of $2.39 billion topped estimates of $2.30 billion. Zoetis also raised its full-year 2026 profit outlook. Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy
• Positive Sentiment: Livestock revenue rose 7% to $797 million, helping offset weaker companion-animal product sales. Zoetis: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: The company narrowed its full-year 2026 revenue guidance while raising its profit outlook, reflecting a stronger earnings outlook alongside a more measured sales picture. Zoetis Announces Third Quarter 2026 Results
• Negative Sentiment: Despite the quarterly beat, revenue declined 1.3% year over year and organic operational revenue fell about 1%. Zoetis also cautioned that pet owners are cutting back on veterinary visits, raising concerns about demand for companion-animal products and the 2027 outlook. Zoetis plans cautiously for 2027 as pet owners cut back on vet visits

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.